Deltagen Inc
Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was incorpo… Read more
Deltagen Inc (DGEN) - Net Assets
Latest net assets as of December 2014: $1.72 Million USD
Based on the latest financial reports, Deltagen Inc (DGEN) has net assets worth $1.72 Million USD as of December 2014.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.84 Million) and total liabilities ($124.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.72 Million |
| % of Total Assets | 93.26% |
| Annual Growth Rate | N/A |
| 5-Year Change | -75.55% |
| 10-Year Change | -82.78% |
| Growth Volatility | 28.75 |
Deltagen Inc - Net Assets Trend (1999–2015)
This chart illustrates how Deltagen Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Deltagen Inc (1999–2015)
The table below shows the annual net assets of Deltagen Inc from 1999 to 2015.
| Year | Net Assets | Change |
|---|---|---|
| 2015-12-31 | $1.67 Million | -2.68% |
| 2014-12-31 | $1.72 Million | +7.25% |
| 2013-12-31 | $1.60 Million | -73.56% |
| 2012-12-31 | $6.05 Million | -11.40% |
| 2010-12-31 | $6.83 Million | -9.00% |
| 2009-12-31 | $7.51 Million | +13.31% |
| 2008-12-31 | $6.62 Million | -0.53% |
| 2007-12-31 | $6.66 Million | -24.55% |
| 2006-12-31 | $8.83 Million | -9.00% |
| 2005-12-31 | $9.70 Million | -68.39% |
| 2002-12-31 | $30.69 Million | -63.33% |
| 2001-12-31 | $83.67 Million | -24.53% |
| 2000-12-31 | $110.86 Million | +821.44% |
| 1999-12-31 | $-15.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Deltagen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21001400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2015)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $39.00K | 2.34% |
| Other Components | $230.10 Million | 13778.38% |
| Total Equity | $1.67 Million | 100.00% |
Deltagen Inc Competitors by Market Cap
The table below lists competitors of Deltagen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sfsb Inc
PINK:SFBI
|
$0.92 |
|
Standard Energy Corp
PINK:STDE
|
$0.92 |
|
China Yanyuan Yuhui National Education Group Inc
PINK:YYYH
|
$0.92 |
|
Santa Fe Petroleum Inc
PINK:SFPI
|
$0.92 |
|
SNM Gobal Holdings
PINK:SNMN
|
$0.91 |
|
Matmown Inc
PINK:MTMW
|
$0.91 |
|
Gooi Global Inc
PINK:GOOI
|
$0.91 |
|
Shengkai Innovations Inc
PINK:VALV
|
$0.91 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Deltagen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2014 to 2015, total equity changed from 1,716,000 to 1,670,000, a change of -46,000 (-2.7%).
- Net loss of 46,000 reduced equity.
- Other comprehensive income decreased equity by 402,000.
- Other factors increased equity by 402,000.
Equity Change Factors (2014 to 2015)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-46.00K | -2.75% |
| Other Comprehensive Income | $-402.00K | -24.07% |
| Other Changes | $402.00K | +24.07% |
| Total Change | $- | -2.68% |
Book Value vs Market Value Analysis
This analysis compares Deltagen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $-14.23 | $0.00 | x |
| 2000-12-31 | $8.78 | $0.00 | x |
| 2001-12-31 | $2.84 | $0.00 | x |
| 2002-12-31 | $0.81 | $0.00 | x |
| 2005-12-31 | $0.25 | $0.00 | x |
| 2006-12-31 | $0.23 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Deltagen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.97%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.08x
- Recent ROE (-2.75%) is above the historical average (-50.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 0.00% | -1116.69% | 0.18x | 0.00x | $-12.31 Million |
| 2000 | -29.06% | -1549.09% | 0.02x | 1.17x | $-43.31 Million |
| 2001 | -57.91% | -488.97% | 0.09x | 1.30x | $-56.82 Million |
| 2002 | -349.24% | -605.81% | 0.21x | 2.69x | $-110.24 Million |
| 2005 | -1.57% | -2.27% | 0.43x | 1.62x | $-1.12 Million |
| 2006 | 49.48% | 44.66% | 1.01x | 1.10x | $3.49 Million |
| 2007 | -1.43% | -2.78% | 0.45x | 1.13x | $-761.00K |
| 2008 | 0.56% | 1.26% | 0.41x | 1.09x | $-625.50K |
| 2009 | -9.15% | -50.63% | 0.17x | 1.03x | $-1.44 Million |
| 2010 | -10.03% | -34.47% | 0.28x | 1.05x | $-1.37 Million |
| 2012 | -19.25% | -110.53% | 0.16x | 1.07x | $-1.77 Million |
| 2013 | -276.13% | -432.29% | 0.50x | 1.28x | $-4.58 Million |
| 2014 | 4.43% | 28.90% | 0.14x | 1.07x | $-95.60K |
| 2015 | -2.75% | -5.97% | 0.43x | 1.08x | $-213.00K |
Industry Comparison
This section compares Deltagen Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Deltagen Inc (DGEN) | $1.72 Million | 0.00% | 0.07x | $0.92 |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |